According to a paper published July 26 in The BMJ, pharmaceutical companies have mostly inconsistent policies regarding trial transparency.
Policies across the 42 companies were described as “highly variable.”
“Of 23 companies eligible from the top 25 companies by revenue, 21 (91 percent) committed to register and trials and 22 (96 percent) committed to share summary results,” according to the paper’s results. ” … However, policies commonly lacked timelines for disclosure, and trials on unlicensed medicines and off-label uses were only included in six (26 percent).”
According to the report, the audit is seemingly “the first structured audit and benchmarking project to examine the transparency policies of pharmaceutical companies.”
Without strict and consistent trial transparency policies, the appraisal of an individual company’s compliance to their police becomes “extremely challenging.”
“Company transparency policies should be explicit, with unambiguous statements describing how compliance is monitored,” the report says.